The severe at-risk group represented patients with high BMI, central obesity, higher VAT, and incidence of MetS (all p<0.05) but there was no association with measures of liver damage (alanine aminotransferase, ALT) or reduced kidney function (estimated glomerular filtration rate, eGFR), all p>0.05 (Table 1—source data 2). This evidence concerns the gene GPT and metabolic syndrome.